New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a...
Kiani’s Speech on Wednesday, at the 6th Global Ministerial Summit on Patient Safety, Will Explore How AI-Based Medical Solutions Can...
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured...
LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 16, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, April 16, 2024 - IRLAB Therapeutics...
TORONTO, ON / ACCESSWIRE / April 15, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its...
Company Announcement, Helsinki, 12 April 2024 at 9 PM (EEST) Nexstim Plc Resolved on a New Stock Option Plan 2024H...
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April...
STUDIO CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and Black Swan Research Initiative® (BSRI)...
- HRZN Originates $33.5 Million of New Loans in Q1 - - HRZN Ends Quarter with Committed Backlog of $168...
Lack of early symptom improvement is not predictive of final responder statusMALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics,...
STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a...
Mississauga, Ontario--(Newsfile Corp. - April 9, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging player in...
The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™...
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a...
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast...
Toronto, Ontario--(Newsfile Corp. - April 7, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or...
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the...